Advertisement
UK markets close in 7 hours 55 minutes
  • FTSE 100

    8,080.93
    +40.55 (+0.50%)
     
  • FTSE 250

    19,621.81
    -97.56 (-0.49%)
     
  • AIM

    753.96
    -0.73 (-0.10%)
     
  • GBP/EUR

    1.1661
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2500
    +0.0038 (+0.30%)
     
  • Bitcoin GBP

    51,400.84
    -2,008.10 (-3.76%)
     
  • CMC Crypto 200

    1,391.35
    +8.78 (+0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,334.40
    -4.00 (-0.17%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,285.99
    +84.72 (+0.49%)
     
  • DAX

    18,001.79
    -86.91 (-0.48%)
     
  • CAC 40

    8,072.30
    -19.56 (-0.24%)
     

Worldwide Precision Medicine Industry to 2025 - Targeted Gene Therapy Presents Opportunities

Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market (2020-2025) by Technology, Sequencing Technology, Products, Applications, End-Users, Route of Administration, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Precision Medicine Market is estimated to be USD 53.5 Bn in 2020 and is expected to reach USD 92.2 Bn by 2025 growing at a CAGR of 11.5%.

The factors such as patient's involvement in personal healthcare, development of technologies such as sequencing technologies, increasing genetic diseases, the growing demand for targeted therapies, and integration of big data healthcare companies with pharma & biotech companies are driving the market growth. The increasing population and rising cancer cases in developing countries in the APAC region like India and China are the major factors propelling the growth of the precision medicine market. The current soaring prices of drug discovery along with the increasing regulatory requirements have pushed the demand for an individualized product.

Favorable government initiatives such as the Precision Medicine Initiative (PMI) launched by the National Institute of Health (NIH) in 2015, helped the market to expand.

However, high diagnostic cost, limited knowledge about Precision Medicine Application, potential threat to the personal data, Lack of Robust Reimbursement Landscape, and stringent regulations hinder the growth of the market.

Market Dynamics

Drivers

  • Advancement of Sequencing Technologies

  • Rising Prevalence of Chronic Diseases

  • Growing Demand for Preventive Care

  • Shifting the Significance in Medicine, from Reaction to Prevention

  • Reducing Adverse Drug Reactions through Pharmacogenomics Test

  • Potential to Reduce the Overall Healthcare Cost Across the Globe

Restraints

  • Unified Framework for Data Integration

  • Limited Knowledge about Precision Medicine Application

  • Lack of Robust Reimbursement Landscape

  • Regulatory Hurdles

ADVERTISEMENT

Opportunities

  • Targeted Gene Therapy

  • Expansion into the Emerging Markets

  • Collaboration and Partnerships across Value Chain Would Accelerate the Market Entry

Challenges

  • High cost of Precision Medicine

  • Violation of the Privacy Rule and Misinterpretation of Genetic and Health Data

  • Reimbursement Challenges

Segments Covered

Based on Technology, The drug discovery market is the fastest-growing segment in the precision medicine market, followed by gene sequencing and companion diagnostics. The growth is attributed to the increasing R&D initiatives by public and private players to develop novel and innovative solutions for the diseases.

Based on Route of Administration, the Oral route is preferred over the various other administration routes due to the many advantages it exhibits. Oral Administration of the medicine has several advantages that include safety, good patient compliance, ease of ingestion, pain avoidance, and versatility to accommodate various types of drugs.

Based on application, the the market has been segmented into Oncology, Central Nervous System, Immunology, Respiratory Medicine, Infections, and others. The oncology segment has a significant share in terms of revenue of the total precision medicine market. However, the immunology segment is expected to witness an impressive CAGR over the forecast period.

Based on End-user, the Pharma & Biotech Companies segment contributes to the major share of the global market. The growth is attributed to the use of innovative technologies in Pharma & Biotech Companies like next-generation sequencing to detect genetic changes linked to the medication. Also, big players in the industry are implementing investment programs to gain substantial market traction.

North America is anticipated to have a large market share and is expected to grow significantly during the forecast period owing to the massive investment in the field of precision medicine in the US. Countries in the Asia Pacific are also expected to grow at an increased incidence of cancer patients, increased acceptance and utilization of precision medicine, and growing awareness in the healthcare sector.

The Global Precision Medicine Market is segmented based on Technology, Sequencing Technology, Products, Applications, End-Users, Route of Administration, and Geography.

Company Profiles
Some of the companies covered in this report are F Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Quest Diagnostics, Laboratory Corporation of America Holdings, AstraZeneca, Amgen Inc., Almac Group Ltd., Bristol-Myers Squibb and Eli Lilly And Compan and others.

Competitive Quadrant
The report includes Infogence Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

  • Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.

  • Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.

  • Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market.

  • Tortoise: Companies that are slow in growth, having a long legacy, and stable or negative in performance.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Precision Medicines Market.

  • The report includes in-depth qualitative analysis, verifiable data from authentic sources and projections about market size. The projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.

  • The report also contains a competitive analysis using the Competitive Quadrant, a Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market including parent industry

  • Important market dynamics and trends

  • Market segmentation

  • Historical, current, and projected size of the market based on value and volume

  • Market shares and strategies of key players

  • Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1. Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2. Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3. Executive Summary

4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Trends

5. Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6. Global Precision Medicine Market, By Technology
6.1 Introduction
6.2 Big data analytics genomics
6.3 Bioinformatics
6.4 Gene sequencing
6.5 Drug discovery
6.6 Companion diagnostics
6.7 Others

7. Global Precision Medicine Market, By Sequencing Technology
7.1 Introduction
7.2 Sequencing by Synthesis (SBS)
7.3 Ion Semiconductor Sequencing (ISS)
7.4 Sequencing by Ligation (SBL)
7.5 Pyrosequencing
7.6 Single Molecule Real Time Sequencing (SMRT)

8. Global Precision Medicine Market, By Products
8.1 Introduction
8.2 Consumables
8.3 Instruments
8.4 Services

9. Global Precision Medicine Market, By Applications
9.1 Introduction
9.2 Oncology
9.3 Central Nervous System (CNS)
9.4 Immunology
9.5 Respiratory Medicine
9.6 Infection
9.7 Other Application

10. Global Precision Medicine Market, By End-Users
10.1 Introduction
10.2 Pharma & Biotech Companies
10.3 Diagnostic Tool Companies
10.4 Healthcare IT/ Big Data Companies
10.5 Clinical Laboratories

11. Global Precision Medicine Market, By Route of Administration
11.1 Introduction
11.2 Oral
11.3 Injectable

12. Global Precision Medicine Market, By Geography
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 South America
12.3.1 Brazil
12.3.2 Argentina
12.4 Europe
12.4.1 UK
12.4.2 France
12.4.3 Germany
12.4.4 Italy
12.4.5 Rest of Europe
12.5 Asia-Pacific
12.5.1 China
12.5.2 Japan
12.5.3 India
12.5.4 Australia
12.5.5 Rest of APAC
12.6 Middle East and Africa

13. Competitive Landscape
13.1 Infogence Competitive Quadrant
13.2 Market Share Analysis
13.3 Competitive Scenario
13.3.1 Mergers & Acquisitions
13.3.2 Agreements, Collaborations, & Partnerships
13.3.3 New Product Launches & Enhancements
13.3.4 Investments & Fundings

14. Company Profiles
14.1 ILLUMINA, INC
14.2 Thermo Fisher Scientific, Inc
14.3 Roche Holding Ag (Roche)
14.4 Laboratory Corporation of America Holdings (LCAH)
14.5 Quest Diagnostics (QD)
14.6 QIAGEN N.V.,
14.7 AstraZeneca
14.8 Novartis Ag (NAG)
14.9 Bristol-Myers Squibb (BMS)
14.10 Eli Lilly & Company (ELC) Omnicell, Inc
14.11 Pfizer Inc.
14.12 Medtronic PLC
14.13 Abbott Laboratories
14.14 Almac Group Ltd.
14.15 Amgen Inc.
14.16 Astellas Pharma Inc.
14.17 ASURAGEN INC.
14.18 Bio-Rad Laboratories, Inc.
14.19 bioMerieux SA
14.20 Bristol-Myers Squibb Company
14.21 CETICS Healthcare Technologies GmbH
14.22 Danaher Corporation
14.23 F. Hoffmann-La Roche AG

15. Appendix
15.1 Questionnaire

For more information about this report visit https://www.researchandmarkets.com/r/9hjwmd

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900